KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacific Biosciences Of California (PACB) Work In Process (2016 - 2026)

Pacific Biosciences Of California has reported Work In Process over the past 15 years, most recently at $27.1 million for Q4 2025.

  • For Q4 2025, Work In Process rose 22.01% year-over-year to $27.1 million; the TTM value through Dec 2025 reached $27.1 million, up 22.01%, while the annual FY2025 figure was $27.1 million, 22.01% up from the prior year.
  • Work In Process for Q4 2025 was $27.1 million at Pacific Biosciences Of California, up from $25.2 million in the prior quarter.
  • Over five years, Work In Process peaked at $27.9 million in Q3 2023 and troughed at $6.9 million in Q1 2021.
  • A 5-year average of $19.3 million and a median of $21.7 million in 2023 define the central range for Work In Process.
  • Biggest five-year swings in Work In Process: surged 135.87% in 2023 and later plummeted 34.4% in 2024.
  • Year by year, Work In Process stood at $8.6 million in 2021, then skyrocketed by 63.3% to $14.1 million in 2022, then skyrocketed by 96.65% to $27.7 million in 2023, then dropped by 19.82% to $22.2 million in 2024, then increased by 22.01% to $27.1 million in 2025.
  • Business Quant data shows Work In Process for PACB at $27.1 million in Q4 2025, $25.2 million in Q3 2025, and $26.9 million in Q2 2025.